Accordingly, while PPAR-α agonists have been shown to protect RPE cells against an oxidative stress in vitro [38] and to reduce angiogenesis in mouse models of neovascular AMD [39], pharmacological inhibition of PPAR-β/δ limited angiogenesis, but exacerbated signs of dry AMD [40]. This evidence concerns the gene PPARA and dry age related macular degeneration.